The price of Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares last traded on Wall Street fell -0.71% to $5.61.
IOVA stock price is now -15.96% away from the 50-day moving average and -36.83% away from the 200-day moving average. The market capitalization of the company currently stands at $1.71B.
With the price target of $17, UBS recently initiated with Buy rating for Iovance Biotherapeutics Inc (NASDAQ: IOVA). On July 29, 2024, Piper Sandler Downgraded its previous ‘Overweight’ rating to ‘Neutral’ on the stock reducing its target price from $19 to quote $10, while ‘Goldman’ rates the stock as ‘Buy’
In other news, Maynard Ryan D, Director sold 50,000 shares of the company’s stock on Nov 12 ’24. The stock was sold for $503,000 at an average price of $10.06. Upon completion of the transaction, the Director now directly owns 7,500 shares in the company, valued at $42075.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 12 ’24, Director Maynard Ryan D bought 50,000 shares of the business’s stock. A total of $503,104 was incurred on buying the stock at an average price of $10.06. A total of 18.95% of the company’s stock is owned by insiders.
During the past 12 months, Iovance Biotherapeutics Inc has had a low of $5.05 and a high of $18.33. As of last week, the company has a debt-to-equity ratio of 0.10, a current ratio of 4.22, and a quick ratio of 3.90.
The net profit margin was -451.25% and return on equity was -56.65% for IOVA. The company reported revenue of $58.55 million for the quarter, compared to $0.47 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 12385.07 percent.
